Merck Announces Full-Year and Fourth-Quarter 2012 Financial Results
Dateline City:
WHITEHOUSE STATION, N.J.
2012 Full-Year Non-GAAP EPS of $3.82, Excluding Certain Items; GAAP EPS of $2.16; Fourth-Quarter Non-GAAP EPS of $0.83, Excluding Certain Items; GAAP EPS of $0.46
2012 Full-Year Worldwide Sales Were $47.3 Billion, a Decrease of 2 Percent, Including a 3 Percent Unfavorable Impact from Foreign Exchange; Fourth-Quarter Worldwide Sales Were $11.7 Billion, a Decline of 5 Percent, Including a 2 Percent Unfavorable Impact from Foreign Exchange
Full-Year and Fourth-Quarter Double-Digit Global Sales Growth for JANUVIA, JANUMET, GARDASIL, VICTRELIS and ZOSTAVAX Offset the Decline in SINGULAIR Sales Following Patent Expiry in the United States
Provides Update on Odanacatib Program; Now Anticipates Filing in 2014
2013 Full-Year Non-GAAP EPS Target of $3.60 to $3.70, Excluding Certain Items; GAAP EPS Range of $2.03 to $2.26
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced financial results for the fourth quarter and full year
of 2012.
Language:
English
Contact HTML:
...
Source: Merck.com - Corporate News - Category: Pharmaceuticals Authors: hq_site_admin Tags: Corporate News Financial News Source Type: news
More News: Cervical Cancer Vaccine | Janumet | Januvia | Merck | Pharmaceuticals | Shingles (Herpes Zoster) Vaccine | Singulair | Varicella-Zoster Virus Vaccine